Ruck13 May 2020 13:13
""There’s been a lot of talk around funding for both the cancer and covid side of the business.""
Well there has on the COVID side simply because it is down to funding whether we get the green light to enter trials, but on the Scancell cancer side I think it has been generally accepted that any update will come once the green light is given for trials, once any funding is finalised to enter COVID 19 into trials, and whereas I thought a funding would take place in April/May after the FDA Approved our trial, I now think Sept/October is more likely given we have no expenditure in regards to trials and should have cut costs accordingly to meet a later deadline.
It was just Knowlesi who picked up on funding late last night, and as keen as I am to see the SP rise he is as keen to see it fall, Ivy has mentioned these updates five times now, well they wont come until we know whether Avidamab will provide us with our first commercial deal, possibly late August and when the COVIDITY funding is in place. I think that is plain common sense, to come from strength, and why sit on millions of trial funding now when we cannot enter trials at least IMHO until end of year or Q1 2021.
So TF agrees with Knowlesi, saying what a wonderful coverage by Trinity Delta, but ignores there 15.6p valuation per share without COVID, which would normally be criticised as Scancell tell them what to say!!!! So what was the wonderful coverage in Trinity Delta, that he refers too.
Seems to me some are trying to suggest we have had long enough to get funding (13 trading days)??? and start 4/5 months earlier about a funding where we have no idea what will occur until then.
Given that there is enormous benefit in getting this funding, not just to reach an SP high for a funding which IMHO we are a fair way off. With the contacts and esteem the universities and Scancell are held in I fully expect to see funding arrive for a platform that has already been validated in cancer and Approved for a combi trial with Keytruda.
Sign In
Follow the stocks
